New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials—the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
While Austria experienced significant political and economic shake-up throughout the 20th century, the country has remained a key strategic market for the pharmaceutical industry thanks to its steady economic development and inclination for innovation.
In the world of patient education, processes, policies, and oversight differ vastly. There is no overarching governance structure. There isn't an accreditation process for educational interventions or patient advocacy organizations that develop the education.
Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve—but the implications in and beyond India are both immediate and lasting.